Superior Detection of Low-allele Burden Janus Kinase 2 V617F Mutation and Monitoring Clonal Evolution in Myeloproliferative Neoplasms Using Chip-based Digital PCR

Overview

Journal Ann Hematol

Specialty Hematology

Date 2024 Jul 23

PMID 39043913

Authors

Yiyi Lu

Lin Lin

Jiafei Lin

Beiying Wu

Gang Cai

Xuefeng Wang

Xuefei Ma

Affiliations

Soon will be listed here.

Abstract

The JAK2 V617F is a prevalent driver mutation in Philadelphia chromosome-negative myeloproliferative neoplasms (PhMPNs), significantly affecting disease progression, immunophenotype, and patient outcomes. The World Health Organization (WHO) guidelines highlight the JAK2 V617F mutation as one of the key diagnostic criterions for PhMPNs. In this study, we analyzed 283 MPN samples with the JAK2 V617F mutation to assess the effectiveness of three detection technologies: chip-based digital PCR (cdPCR), real-time quantitative PCR (qPCR), and next-generation sequencing (NGS). Additionally, we investigated the relationship between JAK2 V617F mutant allele burden (% JAK2 V617F) and various laboratory characteristics to elucidate potential implications in MPN diagnosis. Our findings demonstrated high conformance of cdPCR with qPCR/NGS for detecting % JAK2 V617F, but the mutant allele burdens detected by qPCR/NGS were lower than those detected by cdPCR. Moreover, the cdPCR exhibited high sensitivity with a limit of detection (LoD) of 0.08% and a limit of quantification (LoQ) of 0.2% for detecting % JAK2 V617F in MPNs. Clinical implications were explored by correlating % JAK2 V617F with various laboratory characteristics in MPN patients, revealing significant associations with white blood cell counts, lactate dehydrogenase levels, and particularly β2-microglobulin (β2-MG) levels. Finally, a case report illustrated the application of cdPCR in detecting low-allele burdens in a de novo chronic myeloid leukemia (CML) patient with a hidden JAK2 V617F subclone, which expanded during tyrosine kinase inhibitor (TKI) treatment. Our findings underscore the superior sensitivity and accuracy of cdPCR, making it a valuable tool for early diagnosis and monitoring clonal evolution.

References

Arber D, Orazi A, Hasserjian R, Thiele J, Borowitz M, Le Beau M . The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016; 127(20):2391-405. DOI: 10.1182/blood-2016-03-643544. View

Baxter E, Scott L, Campbell P, East C, Fourouclas N, Swanton S . Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005; 365(9464):1054-61. DOI: 10.1016/S0140-6736(05)71142-9. View

Alshemmari S, Rajan R, Emadi A . Molecular Pathogenesis and Clinical Significance of Driver Mutations in Primary Myelofibrosis: A Review. Med Princ Pract. 2016; 25(6):501-509. PMC: 5588514. DOI: 10.1159/000450956. View

Naumann N, Lubke J, Shomali W, Reiter L, Horny H, Jawhar M . Clinical and histopathological features of myeloid neoplasms with concurrent Janus kinase 2 (JAK2) V617F and KIT proto-oncogene, receptor tyrosine kinase (KIT) D816V mutations. Br J Haematol. 2021; 194(2):344-354. DOI: 10.1111/bjh.17567. View

Vannucchi A, Antonioli E, Guglielmelli P, Longo G, Pancrazzi A, Ponziani V . Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. Leukemia. 2007; 21(9):1952-9. DOI: 10.1038/sj.leu.2404854. View

Lee A, Kim S, Nam J, Yun J, Ryoo H, Bae S . Clinical features and outcomes of V617F-positive polycythemia vera and essential thrombocythemia according to the V617F allele burden. Blood Res. 2021; 56(4):259-265. PMC: 8721460. DOI: 10.5045/br.2021.2021089. View

Barbui T, Thiele J, Gisslinger H, Carobbio A, Vannucchi A, Tefferi A . Diagnostic impact of the 2016 revised who criteria for polycythemia vera. Am J Hematol. 2017; 92(5):417-419. DOI: 10.1002/ajh.24684. View

Cordua S, Kjaer L, Skov V, Pallisgaard N, Hasselbalch H, Ellervik C . Prevalence and phenotypes of V617F and mutations in a Danish general population. Blood. 2019; 134(5):469-479. DOI: 10.1182/blood.2019001113. View

Cordua S, Kjaer L, Skov V, Pallisgaard N, Kefala M, Gjerdrum L . Early detection of myeloproliferative neoplasms in a Danish general population study. Leukemia. 2021; 35(9):2706-2709. DOI: 10.1038/s41375-021-01159-8. View

10.

Langabeer S, Andrikovics H, Asp J, Bellosillo B, Carillo S, Haslam K . Molecular diagnostics of myeloproliferative neoplasms. Eur J Haematol. 2015; 95(4):270-9. DOI: 10.1111/ejh.12578. View

11.

Bench A, White H, Foroni L, Godfrey A, Gerrard G, Akiki S . Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations. Br J Haematol. 2012; 160(1):25-34. DOI: 10.1111/bjh.12075. View

12.

Yi J, Kim H . Coexistence of -positive chronic myeloid leukemia and -mutated myelofibrosis successfully treated with dasatinib and ruxolitinib. Blood Res. 2019; 54(1):77-79. PMC: 6439304. DOI: 10.5045/br.2019.54.1.77. View

13.

Asp J, Skov V, Bellosillo B, Kristensen T, Lippert E, Dicker F . International external quality assurance of JAK2 V617F quantification. Ann Hematol. 2018; 98(5):1111-1118. PMC: 6469832. DOI: 10.1007/s00277-018-3570-8. View

14.

Sims D, Sudbery I, Ilott N, Heger A, Ponting C . Sequencing depth and coverage: key considerations in genomic analyses. Nat Rev Genet. 2014; 15(2):121-32. DOI: 10.1038/nrg3642. View

15.

Ramkissoon L, Montgomery N . Applications of next-generation sequencing in hematologic malignancies. Hum Immunol. 2021; 82(11):859-870. DOI: 10.1016/j.humimm.2021.02.006. View

16.

Gargallo P, Molero M, Bilbao C, Stuckey R, Carrillo-Cruz E, Hermosin L . Next-Generation DNA Sequencing-Based Gene Panel for Diagnosis and Genetic Risk Stratification in Onco-Hematology. Cancers (Basel). 2022; 14(8). PMC: 9030630. DOI: 10.3390/cancers14081986. View

17.

Bacher U, Shumilov E, Flach J, Porret N, Joncourt R, Wiedemann G . Challenges in the introduction of next-generation sequencing (NGS) for diagnostics of myeloid malignancies into clinical routine use. Blood Cancer J. 2018; 8(11):113. PMC: 6232163. DOI: 10.1038/s41408-018-0148-6. View

18.

Kinz E, Leiherer A, Lang A, Drexel H, Muendlein A . Accurate quantitation of JAK2 V617F allele burden by array-based digital PCR. Int J Lab Hematol. 2014; 37(2):217-24. DOI: 10.1111/ijlh.12269. View

19.

Kinz E, Muendlein A . Quantitation of JAK2 V617F Allele Burden by Using the QuantStudio™ 3D Digital PCR System. Methods Mol Biol. 2018; 1768:257-273. DOI: 10.1007/978-1-4939-7778-9_15. View

20.

Link-Lenczowska D, Pallisgaard N, Cordua S, Zawada M, Czekalska S, Krochmalczyk D . A comparison of qPCR and ddPCR used for quantification of the JAK2 V617F allele burden in Ph negative MPNs. Ann Hematol. 2018; 97(12):2299-2308. PMC: 6208664. DOI: 10.1007/s00277-018-3451-1. View